Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The regulation of PD-L1 in non small cell lung cancer

Date

10 Oct 2016

Session

Poster display

Presenters

Soichiro Funaki

Citation

Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362

Authors

S. Funaki1, Y. Shintani2, E. Fukui2, T. Kawamura1, T. Kimura1, R. Kanzaki1, M. Minami1, M. Okumura1

Author affiliations

  • 1 Department Of General Thoracic Surgery, Osaka University Graduate School of Medicine, 565-0871 - Osaka/JP
  • 2 Department Of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka/JP
More

Resources

Background

In cancer immunology, the programmed cell death 1/programmed cell death 1-ligand 1 (PD-1/PD-L1) pathway plays a major role, while anti-PD-1 and anti-PD-L1 antibodies are expected to provide reliable immunotherapy when give as treatment for various types of malignancy including lung cancer. PD-L1 expression in cancer cells has been reported to be a prognostic biomarker as well as a predictive factor for the therapeutic effects of immunotherapy. However, the mechanism of PD-L1 expression remains unclear. Since epithelial mesenchymal transition (EMT) is also known to have a key process in cancer progression, and also to be induced by several factors such as TGF-beta, FGF, and chemotherapy. We investigated the mechanism of PD-L1 expression as well as changes in its expression during the EMT process in non-small lung cancer (NSCLC). In addition, we examined the clinical significance of PD-L1 by analysis of clinical samples from patients with NSCLC.

Methods

To reveal the relationship of PD-L1 expression with the EMT process, A549 (human lung adenocarcinoma cell line) underwent EMT by treatment of TGF-beta or a chemotherapies treatment, then PD-L1 expression was evaluated using RT-PCR and western blotting assays. We also examined alterations of PD-L1 expression through a reverse-EMT process; mesenchymal-epithelial transition (MET) and EMT receptor kinase inhibitors. To elucidate the clinical significance of PD-L1 expression, we performed immunohistochemical staining analysis to evaluate the relationship of PD-L1 expression with EMT status in surgically resected specimens after chemotherapy from 23 patients with NSCLC.

Results

Our results showed that PD-L1 gene expression was up-regulated through TGF-beta -induced EMT or the chemotherapy-induced EMT process, while that was down-regulated by EMT receptor-kinase inhibitor and through MET process. Furthermore, western blotting findings showed that PD-L1 protein changed through both EMT and MET as gene expression patterns. Analysis of clinical samples obtained from NSCLC cases revealed a significant relationship between PD-L1 expression and EMT status.

Conclusions

Our results suggested that PD-L1 expression is regulated by EMT status and those immunotherapies may circumvent the chemoresistance in NSCLC.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

KAKENHI Grants-in-Aid for Scientific Research) Grant-in-Aid for Scientific Research (C).

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings